Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Lee VW, Schwander B, Lee VH. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong. Hong Kong Medical Journal 2013 Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung /drug therapy /genetics /mortality; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms /drug therapy /genetics /mortality; Male; Middle Aged; Mutation; Protein Kinase Inhibitors /economics /therapeutic use; Quinazolines /economics /therapeutic use; Receptor, Epidermal Growth Factor /genetics AccessionNumber 22013052170 Date bibliographic record published 20/12/2013 |